Antibody drug conjugates market is estimated to be worth more than 15 billion in 2030

by Kevin Doe on Aug 2, 2021 Health and Fitness 156 Views

Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “ Antibody Drug Conjugates Market (5th Edition), 2019-2030.”

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of ADCs. 
  • Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain.
  • An insightful competitiveness analysis of biological targets.
  • An analysis of the partnerships that have been established in the recent past.
  • An analysis of the investments made.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products.
  • An assessment of the various therapeutics that are being evaluated in combination with ADCs.
  • A review of the evolution of ADC conjugation technologies.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs.
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 

To sample report – https://www.rootsanalysis.com/reports/270/request-sample.html

 

  • Type of payload
  • MMAE
  • DM4
  • Camptothecin
  • AM1
  • MMAF
  • Type of linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone linker
  • Others
  • Target Indications
  • Breast Cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovaria cancer
  • Others
  • Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Others
  • Small Molecule
  • Technology Providers
  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others
  • Key Geographies
  • North America
  • Europe
  • Asia Pacific

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

  • Alan Burnett (Professor, School of Medicine, Cardiff University)
  • Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • John Burt (Chief Executive Officer, Abzena)
  • Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)

 

Key companies covered in the report

  • Bristol Myers Squibb
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Daiichi Sankyo
  • Pfizer
  • Roche / Genentech
  • Synthon
  • Bayer HealthCare
  • Biotest Pharmaceuticals

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Other Offerings

  1. ADC Contract Manufacturing Market (3rd Edition), 2018-2030
  2. Gene Therapy Market (3rd Edition), 2019 - 2030
  3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Article source: https://article-realm.com/article/Health-and-Fitness/14457-Antibody-drug-conjugates-market-is-estimated-to-be-worth-more-than-15-billion-in-2030.html

Comments

No comments have been left here yet. Be the first who will do it.
Safety

captchaPlease input letters you see on the image.
Click on image to redraw.

Reviews

Guest

Overall Rating:

Most Recent Articles

Latest Comments

It's remarkable to think that just a few years ago, camera drones were essentially gizmos for gadget geeks. Now, they're a crucial creative tool for photographers and filmmakers. A variety of...
Can be immediately applied in practice and death run 3d because that is a good and meaningful article for those who intend and have been living in Russia.
I strongly weaver game recommend buying a separate phone, especially among us if you have your own business.
on Sep 19, 2022 about Essay Proof Reading
Although this article weaver game is negative, it teaches each of us how to live among us ethically and humanely, we live to give and then receive esteem, not selfishly.
on Sep 19, 2022 about DESIGNING COLLEGE
The information you shared is very accurate, it gives me the knowledge that I need to learn. Thank you for sharing this useful information.  the impossible quiz

Recent Reviews

Sep 25, 2022  
bubbly

Sep 19, 2022  
Get Secure and Stable Career at Russia

Sep 19, 2022  
Essay Proof Reading

Sep 13, 2022  
Locked Out of Your Car? Contact a Locksmith

Sep 11, 2022  
nelliexf16

Translate To: